Press Releases - Boehringer Ingelheim
WEBFind the latest press releases from Boehringer Ingelheim on animal health, prescription medicine, pipeline and corporate news.
Boehringer Ingelheim reports strong growth in 2023 and …
WEBApr 16, 2024 · Boehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned.
Boehringer Ingelheim Faces Second Hung Jury in Chicago Zantac …
WEB2 days ago · US News is a recognized leader in college, grad school, hospital, mutual fund, and car rankings. ... The logo of German pharmaceutical company Boehringer Ingelheim is seen at its building in ...
Boehringer’s nerandomilast meets primary ... - Boehringer Ingelheim
WEB5 days ago · Boehringer Ingelheim announced today that the FIBRONEER™-IPF trial met its primary endpoint, which was the absolute change from baseline in Forced Vital Capacity [mL] (FVC) at week 52 versus placebo. FVC is a measure of lung function. 1 Based on these results, Boehringer Ingelheim will submit the new drug application for nerandomilast for the treatment of IPF to the US Food & Drug ...
First half of 2024: Boehringer Ingelheim progresses
WEBJul 18, 2024 · Boehringer Ingelheim, a leading research-driven biopharmaceutical company, reported on Thursday significant progress in its pipeline across key therapeutic areas as it reached major milestones...
Press Releases & Media Information | Boehringer Ingelheim US
WEBClick here to view all of Boehringer Ingelheim's latest press releases, with stories and breaking news on everything in the biopharmaceuticals industry.
First half of 2023: Boehringer Ingelheim sees strong growth and ...
WEBAug 1, 2023 · INGELHEIM, Germany-- (BUSINESS WIRE)--Boehringer Ingelheim, a leading research-driven biopharmaceutical company, continues to advance its pipeline in both Human Pharma and Animal Health...
Boehringer Ingelheim reports strong growth in 2023 and
WEBApr 16, 2024 · Boehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned. Research & Development (R&D) investments...
Boehringer Ingelheim GmbH - The New York Times
WEBHikma Pharmaceuticals agreed to pay about $2.65 billion in cash and shares for Boehringer Ingelheim’s generic drugs business in the United States. By Chad Bray.
Boehringer Ingelheim Begins Clinical Development of First-In …
WEBMay 9, 2023 · Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1
Skip to content